A 32-year-old healthy female with no cardiovascular risk factors developed an acute ST elevation myocardial infarction due to massive left main coronary artery thrombosis 8 months after initiating oral contraceptive pills.
Case Report (n=1)
This case highlights the rare but severe risk of massive coronary artery thrombosis and STEMI associated with oral contraceptive pills in young women without traditional cardiovascular risk factors.
BACKGROUND: The association between oral contraceptive pills and cardiovascular events, including myocardial infarction, has been a subject of debate in the medical literature. While previous studies have suggested a potential link between estrogen-containing contraceptives and an increased risk of thrombotic events, the absolute risk remains low, particularly in young, healthy women without underlying cardiovascular risk factors. CASE PRESENTATION: We report a rare case of a 32-year-old healthy Lebanese female patient with no significant past medical history or cardiovascular risk factors who developed acute coronary syndrome due to coronary artery thrombosis 8 months after initiating oral contraceptive pills (Yasmin tablets; 3.0 mg drospirenone and 0.030 mg ethinyl estradiol). CONCLUSION: This case highlights the need for heightened vigilance and awareness of the potential arterial thrombosis risk associated with oral contraceptive pill use, especially in young women with no other cardiovascular risk factors.
Younes et al. (Fri,) conducted a case report in Acute ST elevation myocardial infarction (n=1). Oral contraceptive pills (Yasmin) was evaluated on Development of acute ST elevation myocardial infarction due to massive left main coronary artery thrombosis. A 32-year-old healthy female with no cardiovascular risk factors developed an acute ST elevation myocardial infarction due to massive left main coronary artery thrombosis 8 months after initiating oral contraceptive pills.